Scientists Demonstrate Pre-clinical Proof of Concept for Next-Gen DNA Delivery Technology

Philadelphia, PA, March 21, 2025 (GLOBE NEWSWIRE) -- Scientists in The Wistar Institute lab of David B. Weiner, Ph.D., in collaboration with scientists in the laboratory of Norbert Pardi, Ph.D., at the University of Pennsylvania Perelman School of Medicine and at the Pennsylvania-headquartered biotechnology company INOVIO, described a next-generation vaccination technology that combines plasmid DNA with a lipid nanoparticle (LNP) delivery system. Their findings are published in Cell Reports Medicine in the paper, “Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity.”
David Weiner, Wistar executive vice president and W.W. Smith Charitable Trust Distinguished Professor in Cancer Research, is a leading expert in the field of DNA vaccines. In the study led by Weiner lab doctoral student Nicholas Tursi, researchers aimed to study how to improve lipid-based formulations to better incorporate and deliver DNA payloads for immunization.
Lipid-based approaches, including LNPs, have successfully formulated and delivered various forms of RNA as well as formulating proteins as drugs in several marketed products. However, developing such formulations using DNA has previously not shown the same stability or efficacy. Tursi et al. studied how to modify lipid-based formulations that would effectively stabilize DNA in LNPs, which would simplify their delivery and improve vaccine-induced immunity. DNA has unique properties relative to RNA, including its large size and double stranded nature, which has previously been a hurdle for creating stable and consistent lipid-based DNA formulations.

DNA vaccines have been traditionally delivered using devices, which enable highly efficient uptake of DNA into cells at the injection site and potent T cell immunity against important disease targets. Utilizing an LNP formulation for DNA vaccines could potentially enable administration by needle and syringe and potentially enhance humoral immunity, which could provide an additional tool within the DNA vaccine toolkit.
Using a model DNA-LNP expressing influenza hemagglutinin (HA), the team examined how to modulate the formulation of DNA within LNPs to improve particle assembly and stability for direct injection. HA DNA-LNPs formulated at higher N/P ratios—the relationship between the lipid nanoparticle and the larger DNA backbone—led to an improved particle profile, smaller particle size, with an improved generation of immune responses.
The study highlights some of the mechanisms of immunity that are conferred by DNA-LNPs.  The team showed that these DNA-LNPs demonstrate a unique way of priming the immune system compared to mRNA and protein-in-adjuvant formulations. The DNA-LNP induced a unique activation pattern of innate immune populations—cells that respond early in the development of a protective immune response. The team next examined whether HA DNA-LNPs could induce strong and consistent adaptive immunity—the arm of the immune system responsible for long lived T cell and antibody responses. Relative to benchmark mRNA and protein-in-adjuvant vaccines, HA DNA-LNPs induced robust antibody and T cell responses after a single dose. Importantly, these responses were durable, with memory responses in small animals persisting beyond a year after immunization. The team also examined the immunogenicity of HA DNA-LNPs in a rabbit model, where they observed strong T cell and antibody responses that persisted into the memory phase. 
Finally, the team examined whether DNA-LNP vaccines could be protective in a live SARS-CoV-2 challenge model. The team utilized a DNA-LNP vaccine expressing the SARS-CoV-2 spike protein and demonstrated that a single immunization with the spike DNA-LNP successfully prevented morbidity and mortality from challenge.
This study supports the continued development DNA-LNP vaccines as a unique vaccination modality. The ability for this approach to trigger strong, long-lasting immune responses highlights its potential to complement existing approaches or be potentially developed as next-generation immunization platform.
Authors: Nicholas J. Tursi1,2, Sachchidanand Tiwari3, Nicole Bedanova1, Toshitha Kannan1, Elizabeth Parzych1, Nisreen M.A. Okba4,5, Kevin Liaw1, András Sárközy3, Cory Livingston1, Maria Ibanez Trullen4,5, Ebony N. Gary1, Máté Vadovics3, Niklas Laenger1,6, Jennifer Londregan2, Mohammad Suhail Khan1, Serena Omo-Lamai7, Hiromi Muramatsu3, Kerry Blatney1, Casey Hojecki1, Viviane Machado8, Igor Marcic8, Trevor R.F. Smith8, Laurent M. Humeau8, Ami Patel1, Andrew Kossenkov1, Jacob S. Brenner7, David Allman2, Florian Krammer4,5,9,10, Norbert Pardi3,, and David B. Weiner1,

1Vaccine and Immunotherapy Center, The Wistar Institute
2Perelman School of Medicine, University of Pennsylvania
3Department of Microbiology, Perelman School of Medicine, University of Pennsylvania
4Department of Microbiology, Icahn School of Medicine at Mount Sinai
5Center for Vaccine Research and Pandemic Preparedness (C-VaRPP), Icahn School of Medicine at Mount Sinai
6Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania
7Biology Department, Saint Joseph’s University
8INOVIO Pharmaceuticals
9Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai
10Ignaz Semmelweis Institute, Interuniversity Institute for Infection Research, Medical University of Vienna

Work supported by: NIH grants R01AI146101, R01AI153064, and P01AI165066; NIH/NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051; and INOVIO Pharmaceuticals SRA 21-05. Additional funding provided by the W.W. Smith Charitable Trust Distinguished Professorship in Cancer Research and The Jill and Mark Fishman Foundation. 

Publication information: “Modulation of lipid nanoparticle-formulated plasmid DNA drives innate immune activation promoting adaptive immunity,” from Cell Reports Medicine

ABOUT THE WISTAR INSTITUTE

The Wistar Institute is the nation’s first independent nonprofit institution devoted exclusively to foundational biomedical research and training. Since 1972, the Institute has held National Cancer Institute (NCI)-designated Cancer Center status. Through a culture and commitment to biomedical collaboration and innovation, Wistar science leads to breakthrough early-stage discoveries and life science sector start-ups. Wistar scientists are dedicated to solving some of the world’s most challenging problems in the field of cancer and immunology, advancing human health through early-stage discovery and training the next generation of biomedical researchers. wistar.org.


Scientists Demonstrate Pre-clinical Proof of Concept for Next-Gen DNA Delivery Technology

Darien Sutton The Wistar Institute 215-870-2048 dsutton@wistar.org

THỦ THUẬT HAY

Những mẹo vặt thú vị khi sử dụng giao diện Gmail mới

Tắt thông báo cho các tin nhắn nhóm là một tính năng khá hữu ích trên iPhone và giờ đây, Gmail cung cấp khả năng tương tự để tắt tiếng các chuỗi email gây phiền. Nếu bạn được đưa vào một email nhóm và không còn quan

Cài đặt Webserver trên máy chủ Amazon Linux AMI

TCN sẽ từng bước hưỡng dẫn các độc giả cài đặt và cấu hình Apache, PHP (với ACP) và MYSQL (LAM) chạy trên máy chủ Linux AMI của Amazon. Hưỡng dẫn này được áp dụng trên máy chủ Amazon Linux AMI nhưng có thể áp dụng cho

Những dịch vụ hỗ trợ hiệu quả cho Dropbox

Dropbox là dịch vụ lữu trữ phổ biến hiện nay, nhưng có một số tính năng cần thiết không được cung cấp trên dịch vụ. Vì vậy, bạn có thể sử dụng thêm 3 dịch vụ để thêm một số tính năng cho dịch vụ này.

Hướng dẫn mang thanh thông báo Android 9 Pie lên các máy khác không cần root

Không như iPhone, các smartphone Android đến từ nhiều nhà sản xuất khác nhau dẫn đến tỉ lệ phân mảnh cao và khó cập nhật phần mềm. Nếu mỗi khi có phiên bản iOS mới rất nhiều đời iPhone được nâng cấp cùng lúc thì đa

Cách tra cứu Bảo hiểm y tế trên thẻ Căn cước công dân rất tiện lợi

Thẻ CCCD gắn chip hỗ trợ tích hợp thẻ Bảo hiểm y tế để mọi người dễ dàng tra cứu qua VNEID. Sau đây là hướng dẫn cách tra cứu Bảo hiểm y tế trên thẻ Căn cước công dân...

ĐÁNH GIÁ NHANH

Tính năng Photographic Styles trên iPhone 13 Series là gì, có gì mới?Sử dụng như thế nào?

Năm nay, Apple trình làng iPhone 13 Series với rất nhiều cải tiến mới về camera. Một trong số đó phải kể đến Photographic Styles. Vậy tính năng Photographic Styles trên iPhone 13 Series là gì? Hãy cùng mình đi tìm hiểu

Đánh giá máy tính bảng Kingcom Piphone Pluto: thiết kể đơn giản, hiệu năng đủ dùng

Kingcom Piphone Pluto là mẫu máy tính bảng chạy vi xử lý Intel SoFIA và có khả năng hỗ trợ nghe gọi, đàm thoại như những smartphone thông thường.

So sánh thiết kế Sharp Aquos S2 và iPhone X: Những smartphone tiên phong cho xu hướng tràn viền

Trước khi đi vào phần so sánh chi tiết, TCN muốn gửi đến quý độc giả một thông tin. Đó là ngày ra mắt toàn cầu của Sharp Aquos S2 là ngày 8 tháng 8 2017, trong khi đó iPhone X được ra mắt toàn cầu vào ngày 12 tháng 9